GOSSAMER BIO, INC. Customer Breakdown
Customer relationships and concentrations across all retained periods. Named customers and their revenue are shown when disclosed. Anonymous customers, customer groups and sales channels are labelled separately. Receivable concentration measures unpaid balances, not revenue contribution. A biggest customer by revenue can be identified only from disclosed customer revenue. Missing names and amounts remain missing; identities are not assumed to match between periods.
| Period / as of | Customer / group | Category | Customer revenue | Share of revenue | Share of trade receivables | Basis and limitations |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | | $6.326B | 25.62 |
|---|